| 【英語タイトル】Global Cholera Vaccines Market Size study & Forecast, by Vaccine Type (Whole cell V. cholerae O1 with Recombinant B-subunit, and Killed Oral O1, and O139), by Product (Vaxchora, Dukoral, Shanchol and Other Products) and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23FB133
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年1月25日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：医療
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社の本調査レポートは、2021年に86.5百万ドルであった世界のコレラワクチン市場規模が、2022年から2029年の間に8.20%成長すると予想しています。本レポートでは、コレラワクチンの世界市場について調査し、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、ワクチン種類別（組換えBサブユニットを有する全細胞コレラ菌 O1、不活化経口O1＆O139）分析、製品別（Vaxchora、Dukoral、Shanchol、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争状況、調査プロセスなどの項目を掲載しています。また、本書には、MitsubishiTanabePharmaCorporation、TakedaPharmaceuticalCo.,Ltd.、AstraZeneca、GlaxoSmithKlineplc(GSK)、ShanthaBiotechnicsPrivateLimited、ValnevaSE、AstellasPharma,Inc.、EmergentBioSolutions,Inc.、Pfizer,Inc.、Merck&Co.,Inc.などの企業情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界のコレラワクチン市場規模：製品別
- Vaxchoraの市場規模
- Dukoralの市場規模
- Shancholの市場規模
- その他製品の市場規模
・世界のコレラワクチン市場規模：ワクチン種類別
- 組換えBサブユニットを有する全細胞コレラ菌 O1の市場規模
- 不活化経口O1＆O139の市場規模
・世界のコレラワクチン市場規模：地域別
- 北米のコレラワクチン市場規模
- ヨーロッパのコレラワクチン市場規模
- アジア太平洋のコレラワクチン市場規模
- 南米のコレラワクチン市場規模
- その他地域のコレラワクチン市場規模
・競争状況
・調査プロセス |
Global Cholera Vaccines Market is valued at approximately USD 86.5 million in 2021 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period 2022-2029. Vibrio cholera, which causes cholera, is spread by the intake of contaminated food or water. The infected people experience acute watery diarrhea, which eventually results in dehydration. If this condition is left untreated, the water loss might result in death. In order to avoid cholera epidemics, oral immunization has been found to be the most effective prophylactic measure. The market growth is driven by key players such as high incidence of cholera and rise in the number of initiatives to control cholera
The market for cholera vaccines is expanding as a result of several causes, including rising public and private sector activities, rising cholera prevalence, and increased global awareness of the disease. According to the World Health Organization, there were between 1.3 to 1.4 million cases of cholera reported in 2020 throughout all nations, including 17 in Africa, 12 in Asia, 4 in Europe, and 4 in the Americas. Eighty percent of all cases were in Haiti, the Demographic Republic of the Congo, Vietnam, Yemen, Peru, Somalia, and Tanzania. However, adverse effects of vaccines stifle market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Cholera Vaccines Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia Pacific is recorded to be the largest region owing to high incidence rate, growing awareness, and availability of efficient preventive solutions. However, North America is expected to be the fastest growing region due to number of people traveling to countries with sudden outbreaks of cholera is increasing and demand for immunization is growing.
Major market players included in this report are:
Mitsubishi Tanabe Pharma Corporation
Takeda Pharmaceutical Co., Ltd.
AstraZeneca
GlaxoSmithKline plc (GSK)
Shantha Biotechnics Private Limited
Valneva SE
Astellas Pharma, Inc.
Emergent BioSolutions, Inc.
Pfizer, Inc.
Merck & Co., Inc.
Recent Developments in the Market:
In May 2022, more than 1.9 million children in Malawi are the target of a cholera immunisation campaign started by the World Health Organization Africa.
In June 2022, an oral cholera immunisation programme was started by the Ministry of Health and Partners in the Juba Country of Central Equatoria State. The campaign is a component of a plan of action to stop cholera outbreaks in the identified hotspot region.
Global Cholera Vaccines Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Vaccine type, Product, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Vaxchora
Dukoral
Shanchol
Other Products
By Vaccine Type:
Whole cell V. cholerae O1 with Recombinant B-subunit
Killed Oral O1 and O139
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. Cholera Vaccine Market, by Region, 2019-2029 (USD Million)
1.2.2. Cholera Vaccine Market, by Vaccine Type, 2019-2029 (USD Million)
1.2.3. Cholera Vaccine Market, by Product, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Cholera Vaccine Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Cholera Vaccine Market Dynamics
3.1. Cholera Vaccine Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. High incidence of cholera
3.1.1.2. Rise in the number of initiatives to control cholera
3.1.2. Market Challenges
3.1.2.1. Adverse effects of vaccines
3.1.3. Market Opportunities
3.1.3.1. Rising awareness about cholera preventive care
3.1.3.2. Rise in cholera vaccines across the world
Chapter 4. Global Cholera Vaccine Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Cholera Vaccine Market, by Vaccine Type
6.1. Market Snapshot
6.2. Global Cholera Vaccine Market by Vaccine Type, Performance – Potential Analysis
6.3. Global Cholera Vaccine Market Estimates & Forecasts by Vaccine Type 2019-2029 (USD Million)
6.4. Cholera Vaccine Market, Sub Segment Analysis
6.4.1. Whole cell V. cholerae O1 with Recombinant B-subunit
6.4.2. Killed Oral O1 and O139
Chapter 7. Global Cholera Vaccine Market, by Product
7.1. Market Snapshot
7.2. Global Cholera Vaccine Market by Product, Performance – Potential Analysis
7.3. Global Cholera Vaccine Market Estimates & Forecasts by Product 2019-2029 (USD Million)
7.4. Cholera Vaccine Market, Sub Segment Analysis
7.4.1. Vaxchora
7.4.2. Dukoral
7.4.3. Shanchol
7.4.4. Other Products
Chapter 8. Global Cholera Vaccine Market, Regional Analysis
8.1. Cholera Vaccine Market, Regional Market Snapshot
8.2. North America Cholera Vaccine Market
8.2.1. U.S. Cholera Vaccine Market
8.2.1.1. Vaccine Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Product breakdown estimates & forecasts, 2019-2029
8.2.2. Canada Cholera Vaccine Market
8.3. Europe Cholera Vaccine Market Snapshot
8.3.1. U.K. Cholera Vaccine Market
8.3.2. Germany Cholera Vaccine Market
8.3.3. France Cholera Vaccine Market
8.3.4. Spain Cholera Vaccine Market
8.3.5. Italy Cholera Vaccine Market
8.3.6. Rest of Europe Cholera Vaccine Market
8.4. Asia-Pacific Cholera Vaccine Market Snapshot
8.4.1. China Cholera Vaccine Market
8.4.2. India Cholera Vaccine Market
8.4.3. Japan Cholera Vaccine Market
8.4.4. Australia Cholera Vaccine Market
8.4.5. South Korea Cholera Vaccine Market
8.4.6. Rest of Asia Pacific Cholera Vaccine Market
8.5. Latin America Cholera Vaccine Market Snapshot
8.5.1. Brazil Cholera Vaccine Market
8.5.2. Mexico Cholera Vaccine Market
8.5.3. Rest of Latin America Cholera Vaccine Market
8.6. Rest of The World Cholera Vaccine Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Mitsubishi Tanabe Pharma Corporation
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Takeda Pharmaceutical Co., Ltd.
9.2.3. AstraZeneca
9.2.4. GlaxoSmithKline plc (GSK)
9.2.5. Shantha Biotechnics Private Limited
9.2.6. Valneva SE
9.2.7. Astellas Pharma, Inc.
9.2.8. Emergent BioSolutions, Inc.
9.2.9. Pfizer, Inc.
9.2.10. Merck & Co., Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption
